#United States #NASDAQ #Salt Lake City #Co-Diagnostics #Silicon Slopes

Co-Diagnostics, Inc. to Make Waves at Nasdaq's Live Broadcast

Co-Diagnostics, Inc. (Nasdaq-CM: CODX), a pioneering player in molecular diagnostics, is gearing up to showcase its cutting-edge technologies at the renowned Nasdaq Live from MarketSite event scheduled for January 14, 2025, during the Silicon Slopes Summit. This event is significant as it highlights forward-thinking companies that are reshaping their respective fields.

CEO Dwight Egan will lead the discussion, providing insights into the company's innovative Co-Dx PCR platform. This platform is uniquely designed to develop various molecular diagnostic tests, positioning Co-Diagnostics to effectively tackle current and emerging health crises. The focus will include tests for COVID-19, tuberculosis, and HPV, as well as a multiplex panel for respiratory infections.

Addressing Emerging Health Threats

The interview will also cover how Co-Diagnostics is preparing for potential future health threats, such as the human metapneumovirus (HMPV), H5N1 avian flu, and mpox (formerly known as monkeypox). With the ongoing uncertainty surrounding infectious diseases, Co-Dx aims to be at the forefront of developing relevant testing solutions. For instance, their Co-Dx™ Logix Smart® ABC test efficiently detects all known circulating strains of H5N1. Currently available for qualified centralized laboratories and categorized as a Research Use Only (RUO) assay in the United States, this test holds promise for broader applications in regions acknowledging CE marking as valid regulatory clearance.

Co-Diagnostics has also advanced its analytical processes for mpox testing, successfully confirming that its current 2-gene RUO test maintains full effectiveness against circulating strains over the past year. Consequently, an update is in the works to introduce a new 3-gene version tailored to regional demands.

Navigating the COVID-19 Landscape

The post-holiday spike in COVID-19 infections serves as a stark reminder of the pandemic's ongoing threat. Health experts are cautioning that the pandemic is far from over, and variants continue to pose risks. Co-Diagnostics is steadfast in its commitment to staying prepared for such fluctuations. As part of the Nasdaq broadcast, they will discuss existing protocols and testing mechanisms aimed at addressing these emerging challenges collectively.

Upon its broadcast, the interview will be accessible via Nasdaq’s Live from MarketSite webpage and through Co-Diagnostics’ social media platforms, broadening its reach to health professionals, researchers, and the public.

Looking Ahead

Co-Diagnostics, Inc., a corporation based in Utah, is characterized by its innovative methodologies in developing, manufacturing, and offering state-of-the-art diagnostic technologies. Specialized in tests that leverage the detection and analysis of nucleic acids (DNA and RNA), their proprietary technology is also instrumental in pinpointing genetic markers applicable to various fields beyond infectious disease testing.

In summary, the participation of Co-Diagnostics at the Nasdaq event is not merely an opportunity to highlight their ongoing advancements but also a critical step in promoting readiness for future health challenges. Their contributions to molecular diagnostics signify an essential pillar in public health infrastructure, helping to safeguard communities against infectious disease threats.

This participation embodies the proactive approach necessary in today's unpredictable health environment, demonstrating how one company is striving to stay ahead of the curve through innovation and dedication to public health. The developments shared during this event promise to shape not only the future strategies of Co-Diagnostics but also the standards for diagnostic testing in infectious diseases.